Omega-3 Fatty Acid EPA Linked to Improved Survival in Colorectal Cancer Liver Metastases

The Phase 3 EMT2 trial results, presented at ESMO Congress 2026, indicate that high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, significantly improved overall survival for patients with colorectal cancer liver metastases. Patients receiving EPA before and after surgery showed an estimated five-year overall survival of 62.0% versus 45.1% for placebo, reducing the hazard of death by 32%. The treatment was well-tolerated without increased adverse events.